Cargando…
Tocilizumab Effects on Coagulation Factor XIII in Patients with Rheumatoid Arthritis
INTRODUCTION: Rheumatoid arthritis (RA) is a chronic systemic auto-immune disease associated with a prothrombotic state. Tocilizumab, an interleukin-6 receptor inhibitor, is highly effective in controlling disease activity and thrombotic risk. Factor XIII (FXIII), involved in thrombotic complication...
Autores principales: | Gualtierotti, Roberta, Ingegnoli, Francesca, Boscolo, Massimo, Griffini, Samantha, Grovetti, Elena, Cugno, Massimo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6860466/ https://www.ncbi.nlm.nih.gov/pubmed/31654331 http://dx.doi.org/10.1007/s12325-019-01118-x |
Ejemplares similares
-
Disease-modifying anti-rheumatic drugs improve the cardiovascular profile in patients with rheumatoid arthritis
por: Giachi, Andrea, et al.
Publicado: (2022) -
Activation of Blood Coagulation in Two Prototypic Autoimmune Skin Diseases: A Possible Link with Thrombotic Risk
por: Cugno, Massimo, et al.
Publicado: (2015) -
Complement activation in patients with COVID-19: A novel therapeutic target
por: Cugno, Massimo, et al.
Publicado: (2020) -
Practical Management of Cardiovascular Comorbidities in Rheumatoid Arthritis
por: Gualtierotti, Roberta, et al.
Publicado: (2017) -
Tocilizumab Induced Acquired Factor XIII Deficiency in Patients with Rheumatoid Arthritis
por: Mokuda, Sho, et al.
Publicado: (2013)